Faron Pharmaceuticals Oy New data published on Clever-1 function
September 12 2018 - 2:01AM
RNS Non-Regulatory
TIDMFARN
Faron Pharmaceuticals Oy
12 September 2018
Faron Pharmaceuticals Ltd
("Faron" or the "Company")
Clever-1 participates in the control of humoral
(antibody-mediated) immunity
- New data published by Frontiers in Immunology
TURKU - FINLAND, 12 September 2018 - Faron Pharmaceuticals Ltd
("Faron") (AIM: FARN), the clinical stage biopharmaceutical
company, announces today new data on Clever-1 function in the
control of antibody production by B-lymphocytes (B cells).
Clever-1, a cell surface receptor expressed mainly by
endothelial cells and monocytes/macrophages, has previously been
shown to control cell-mediated immunity (Palani et al. 2016). The
recent work by Dunkel and colleagues, published online by Frontiers
in Immunology, shows for the first time that Clever-1 also
participates in the control of B cell response and humoral antibody
production. The data suggest that Clever-1 serves as an endogenous
immunosuppressive molecule in monocytes/macrophages, where it
maintains the production of inflammatory cytokines at physiological
levels. When Clever-1 is removed from monocytes/macrophages, one
consequence of the unrestrained production of inflammatory
cytokines is the increased antibody production by B cells.
Deleting or neutralizing Clever-1 has previously been reported
to augment antitumor immune responses in melanoma, lymphoma and
breast cancer. The efficacy of anti-Clever-1 antibodies in these
experimental models supports Faron's development of Clevegen, its
fully human anti-Clever-1 antibody, under investigation as a
potential cancer immunotherapy and due to enter the clinic later
this year.
The observations by Dunkel et al suggest that disrupting the
function of Clever-1 should not lead to the suppression of antibody
production but, rather, could improve humoral immune responses
against tumor antigens and during vaccinations.
Commenting on this finding, Dr Markku Jalkanen, CEO of Faron,
said: "This is a fascinating finding and builds up further evidence
for the importance to control Clever-1 function in conditions where
active immune suppression can cause disease or worsen disease
development. It provides further scientific rationale for our
Vaccination Response Enhancement Technology (VRET) programme, which
is currently under early investigation with Clevegen."
Referred article: Dunkel J, Viitala M, Karikoski M, Rantakari P,
Virtakoivu R, Hollmén M, Jalkanen S and Salmi M. Macrophage
Clever-1 regulates antibody production. Frontiers in Immunolgy. On
line code Front. Immunol. | doi: 10.3389/fimmu.2018.02257
https://www.frontiersin.org/articles/10.3389/fimmu.2018.02257/abstract
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Matthew Neal, Lindsey
Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com
About Faron Pharmaceuticals Ltd
Faron (AIM:FARN) is a clinical stage biopharmaceutical company
developing novel treatments for medical conditions with significant
unmet needs. The Company currently has a pipeline focusing on acute
organ traumas, vascular damage and cancer immunotherapy. The
Company's lead candidate Traumakine, to prevent vascular leakage
and organ failures, has completed a Phase III clinical trial in
Acute Respiratory Distress Syndrome (ARDS). An additional European
Phase II Traumakine trial is underway for the Rupture of Abdominal
Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a
ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has
the ability to switch immune suppression to immune activation in
various conditions, with potential across oncology, infectious
disease and vaccine development. This novel macrophage-directed
immuno-oncology switch called Tumour Immunity Enabling Technology
("TIET") may be used alone or in combination with other immune
checkpoint molecules for the treatment of cancer patients. Faron is
based in Turku, Finland. Further information is available at
www.faron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABFLLFVKFEBBL
(END) Dow Jones Newswires
September 12, 2018 02:01 ET (06:01 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024